| Name | Title | Contact Details |
|---|
Conventional approaches aren't getting the job done so we've taken a whole new approach to helping individuals make more informed, confident choices. We've built a company for the sole purpose of engaging and delighting your employees and supporting them with every health benefits or healthcare question they have. We've proven that by giving employees and their families a great service and helping them get the right care that we can create more satisfied and committed employees and lower healthcare costs for employers. We've aligned our people, processes and technology to do the hard work of simplifying healthcare. We partner with large, innovative and forward-thinking organizations that share the belief that taking care of their employees when they need it most, is good for their business.
Nexeon MedSystems, Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
One GI is a physician-centric gastroenterology management services organization (MSO) that partners with gastroenterologists to help them manage, optimize, and grow their independent gastroenterology practices.
Our mission—empowering our customers to achieve their best health—exemplifies our commitment to look at healthcare differently. But even more importantly, we look at you, the customer, differently. We believe that healthcare can be better and this is what really drives us. At North Memorial Health, you have a voice and we listen. You have health goals and we have the knowledge and the tools to help you get there. Even when illness or injury steals your strength, we will not let it steal your power. We believe when you`re engaged and informed, you will have better health and a better life.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.